Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study

Medicine (United States)

Volumn 97, Issue 3, 2018, Pages

  Yu, Wen Chang ^a   Zhang, Kong Zhi ^a   Chen, Shi Guang ^b   Liu, Wei Fu ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Provincial Key Laboratory of Environmental Engineer   (China)

Author keywords

apatinib; efficacy; hepatocellular carcinoma; safety; targeted therapy

Indexed keywords

AMINOTRANSFERASE; APATINIB; BILIRUBIN; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; LABORATORY TEST; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; AGED; LIVER TUMOR; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041472350     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000009704     Document Type: Article

References (27)

1. Ferlay J., Shin HR, Bray F. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Ge S., Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther 2015; 9: 352-62.
3. Bruix J., Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.
4. Llovet JM, Ducreux M., Lencioni R. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
5. Capussotti L., Muratore A., Amisano M. Liver resection for hepatocellular carcinoma on cirrhosis: Analysis of mortality, morbidity and survival-A European single center experience. Euro J Surg Oncol 2005; 31: 986-93.
6. Facciorusso A., Serviddio G., Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 2016; 7: 477-89.
7. Kamo N., Kaido T., Yagi S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016; 5: 391-8.
8. Liu PH, Hsu CY, Hsia CY. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma < /= 2 cm in a propensity score model. Annals Surg 2016; 263: 538-45.
9. Llovet JM, Real MI, Montana X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-9.
10. Lo CM, Ngan H., Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
12. Qin S., Bai Y., Lim HY. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clinical Oncol 2013; 31: 3501-8.
13. Llovet JM, Ricci S., Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. New England J Med 2008; 359: 378-90.
14. Cheng AL, Kang YK, Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
15. Scott AJ, Messersmith WA, Jimeno A. Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today 2015; 51: 223-9.
16. Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Dev Ther 2015; 9: 6075-81.
17. Hu X., Cao J., Hu W. Multicenter phase II study of apatinib in non-Triple-negative metastatic breast cancer. BMC cancer 2014; 14: 820-7.
18. Fang SC, Zhang HT, Zhang YM. Apatinib as post second-line therapy in EGFR wild-Type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther 2017; 10: 447-52.
19. Eisenhauer EA, Therasse P., Bogaerts J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
20. Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. American J Health Syst Pharm 2004; 61: S4-11.
21. Ferrara N., Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
22. Li J., Qin S., Xu J. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 2016; 34: 1448-54.
23. Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. J Clin Oncol 2014; 32
24. Lim HY, Heo J., Choi HJ. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014; 20: 5976-85.
25. Fan M., Zhang J., Wang Z. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-Angiogenic therapy. Breast Cancer Res Treat 2014; 143: 141-51.
26. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability. Clin Liver Dis 2015; 19: 223-38.
27. Nakano M., Tanaka M., Kuromatsu R. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: A prospective multicenter cohort study. Cancer Med 2015; 4: 1836-43.